Adenoid cystic carcinoma (ACC) is a rare and aggressive form of cancer that typically arises in the salivary glands, but can also occur in other areas such as the breast, trachea, or lungs. Despite its rarity, ACC poses significant challenges due to its slow growth and tendency to spread to distant organs, particularly the lungs. Research efforts in cancer biology and treatment strategies are intensifying to combat this disease. Scientists are investigating the genetic mutations and molecular pathways underlying ACC to identify potential targets for therapy. Immunotherapy, targeted therapies, and combination treatments are being explored in clinical trials to improve outcomes for patients with ACC. Moreover, advances in precision medicine hold promise for tailoring treatments to the individual characteristics of each patient's tumor, offering new hope in the fight against this challenging cancer.
Title :
Pietro Salvatori, Private Practice, Italy
Title :
Jianhua Luo, University of Pittsburgh, United States
Title :
Marika Crohns, Sanofi, Germany
Title : RNA binding proteins in the pathogenesis of pediatric cancer
Atif A Ahmed, University of Washington-Seattle Children’s Hospital, United States
Title : A novel mRNA genomic technology for precision medicine, early cancer diagnosis, prognosis, treatment follow-up and cancer gene therapy
Rajvir Dahiya, University of California San Francisco, United States
Title : The future of pharmacogenetic polymorphism, pharmacogenomics and pharmamicrobiome in cancer treatment
Bene Ekine-Afolabi, University of East London, United Kingdom